TrialBMC research notes2014

FOLFIRI® and bevacizumab in first-line treatment for colorectal cancer patients: safety, efficacy and genetic polymorphisms.

Yves Bécouarn et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.